Showing results (371-380 of 3,351) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|December 16, 2019
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trialsAlexander Drilon, Salvatore Siena, Rafal Dziadziuszko, et al.
The Lancet. Oncology|March 6, 2020
Radiotheranostics: a roadmap for future developmentKen Herrmann, Markus Schwaiger, Jason S Lewis, et al.
The Lancet. Oncology|March 6, 2020
CAR T cells: continuation in a revolution of immunotherapyAnurag K Singh, Joseph P McGuirk
The Lancet. Oncology|March 14, 2020
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trialChiara Cremolini, Carlotta Antoniotti, Daniele Rossini, et al.
The Lancet. Oncology|December 8, 2018
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trialCarol Moreno, Richard Greil, Fatih Demirkan, et al.
The Lancet. Oncology|January 12, 2019
Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup studyJacoline E C Bromberg, Samar Issa, Katerina Bakunina, et al.
The Lancet. Oncology|November 2, 2019
Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic reviewNing Li, Hui-Yao Huang, Da-Wei Wu, et al.
The Lancet. Oncology|December 2, 2019
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trialPeter Schmid, Hope S Rugo, Sylvia Adams, et al.
The Lancet. Oncology|December 5, 2019
Global public and philanthropic investment in childhood cancer research: systematic analysis of research funding, 2008-16Eva M Loucaides, Elizabeth J A Fitchett, Richard Sullivan, et al.
The Lancet. Oncology|December 5, 2019
Prognostic value of patient-reported outcomes from international randomised clinical trials on cancer: a systematic reviewJustyna Mierzynska, Claire Piccinin, Madeline Pe, et al.
Pageof 336